Sorry, it seems JavaScript is not enabled in your browser. Please enable it to get the best site experience.

Z-FA-FMK | CAS 197855-65-5 | SCBT - Santa Cruz Biotechnology
Z-FA-FMK CAS: 197855-65-5
MF: C21H23FN2O4
MW: 386.42
Inhibits effector, but not initator caspases in vitro, and suppress some forms of apoptosis.

Z-FA-FMK (CAS 197855-65-5)

Z-FA-FMK | CAS 197855-65-5 is rated 5.0 out of 5 by 1.
  • y_2023, m_2, d_4, h_21
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.34
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_201303, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getAggregateRating, 104ms
  • REVIEWS, PRODUCT
loading
5
1
4
0
3
0
2
0
1
0
Alternate Names: Z-Phe-Ala fluoromethyl ketone
Application: Z-FA-FMK is inhibits effector, but not initator caspases in vitro, and suppress some forms of apoptosis
CAS Number: 197855-65-5
Purity: ≥95%
Molecular Weight: 386.42
Molecular Formula: C21H23FN2O4
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data (including water content).
loading

Z-FA-FMK is an irreversible inhibitor of cysteine proteases, such as cathepsin B, L, and S, that do not require a P1 Asp residue. The compound has also inhibitited papain and cruzain. Z-FA-FMK has been shown to selectively inhibit effector caspase-2, caspase-3, caspase-6, and caspase-7 without affecting initiator caspase-8 and caspase-10 while showing minimal toxicity to normal mammalian cells in vitro. Due to Z-FA-FMK's effector caspase specificity, the compound has been recorded to inhibit some forms of caspase mediated apoptosis. The compound has been observed to be an effective in time dependent inactivation of cathepsin B isozymes from a number of tissues. Studies show Cathepsin B-like activity plays a role in the cascade of proteolytic cartilage destruction. Z-FA-FMK is an inhibitor of cathepsin H.


References

1. Shaw, E., et al. 1981. Meth. Enzymol. 80: 820-826. PMID: 7043207
2. Smith, R.E., et al. 1988. Anticancer Res. 8: 525-529. PMID: 3178145
3. Van Noorden, C.J., et al. 1988. J. Rheumatol. 15: 1525-1535. PMID: 3204599
4. Brömme, D., et al. 1989. Biochem. J. 264: 475-481. PMID: 2604727
5. Ahmed, N.K., et al. 1992. Biochem. Pharmacol. 44: 1201-1207. PMID: 1417942
6. Harth, G., et al. 1993. Mol. Biochem. Parasitol. 58: 17-24. PMID: 8459830
7. McGrath, M.E., et al. 1995. J. Mol. Biol. 247: 251-259. PMID: 7707373
8. Lotem, J., et al. 1996. Proc. Natl. Acad. Sci. U.S.A. 93: 12507-12512. PMID: 8901612
9. Eichhold, T.H., et al. 1997. J Pharm Biomed Anal. 16: 459-467. PMID: 9589405
10. Schotte, P., et al. 2001. J. Biol. Chem. 276: 21153-21157. PMID: 11290751
11. Guo, M., et al. 2002. J. Biol. Chem. 277: 14829-14837. PMID: 11815600
12. Lopez-Hernandez, F.J., et al. 2003. Mol. Cancer Ther. 2: 255-263. PMID: 12657720

Physical State :
Solid
Solubility :
Soluble in DMSO (10 mM).
Storage :
Store at -20° C
Melting Point :
~226.14° C (Predicted)
Boiling Point :
630.54° C at 760 mmHg
Density :
1.21 g/cm3
Refractive Index :
n20D 1.55
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
WGK Germany :
3
PubChem CID :
MDL Number :
MFCD00883668
SMILES :
CC(C(=O)CF)NC(=O)C(CC1=CC=CC=C1)NC(=O)OCC2=CC=CC=C2

Download SDS (MSDS)

Certificate of Analysis

Adobe Acrobat Reader is required to reliably view,
print and comment on PDF documents

Z-FA-FMK (CAS 197855-65-5)  Product Citations

See how others have used Z-FA-FMK (CAS 197855-65-5). Click on the entry to view the PubMed entry .

Citations 1 to 10 of 18 total
Citations 1 to 10 of 18 total

Can this cross the blood-brain barrier?

Asked by: ChemSynth123
Thank you for your question. This chemical, Z-FA-FMK (CAS 197855-65-5): sc-201303, has not been proven to cross the blood-brain barrier. All journal articles that reference Z-FA-FMK describe in vitro use.
Answered by: Technical Support
Date published: 2016-12-14
  • y_2023, m_2, d_4, h_21CST
  • bvseo_bulk, prod_bvqa, vn_bulk_3.0.34
  • cp_1, bvpage1
  • co_hasquestionsanswers, tq_1
  • loc_en_US, sid_201303, prod, sort_[SortEntry(order=LAST_APPROVED_ANSWER_SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 105ms
  • QUESTIONS, PRODUCT
Rated 5 out of 5 by from Rajah Rajah, T. et al. (PubMed 25915766) demonstrated that the inhibition of T cell activation and proliferation mediated by z-FA-FMK, an irreversible inhibitor of cathepsins B, L, and S, cruzain and papain, is due to oxidative stress via the depletion of GSH. -SCBT Publication Review
Date published: 2015-04-18
  • y_2023, m_2, d_4, h_21
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.34
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_201303, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getReviews, 17ms
  • REVIEWS, PRODUCT